Durvalumab and bevacizumab plus transarterial chemoembolization in unresectable hepatocellular carcinoma: a new paradigm?

Maen Abdelrahim, Abdullah Esmail, Bandar Al-Judaibi

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Article number1
JournalTranslational Gastroenterology and Hepatology
Volume11
DOIs
StatePublished - Jan 30 2026

Keywords

  • bridging therapy
  • checkpoint inhibitors
  • Hepatocellular carcinoma (HCC)
  • liver transplant
  • Milan criteria

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Divisions

  • Medical Oncology

Cite this